[go: up one dir, main page]

NO20005461L - Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever - Google Patents

Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever

Info

Publication number
NO20005461L
NO20005461L NO20005461A NO20005461A NO20005461L NO 20005461 L NO20005461 L NO 20005461L NO 20005461 A NO20005461 A NO 20005461A NO 20005461 A NO20005461 A NO 20005461A NO 20005461 L NO20005461 L NO 20005461L
Authority
NO
Norway
Prior art keywords
sub
hypertension
treatment
obesity
fatty acid
Prior art date
Application number
NO20005461A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005461D0 (no
Inventor
Rolf Berge
Original Assignee
Thia Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica filed Critical Thia Medica
Priority to NO20005461A priority Critical patent/NO20005461L/no
Publication of NO20005461D0 publication Critical patent/NO20005461D0/no
Publication of NO20005461L publication Critical patent/NO20005461L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20005461A 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever NO20005461L (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20005461A NO20005461L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (fr) 1998-05-08 1998-05-08 Utilisation d'analogues d'acides gras non beta-oxydables pour traiter les etats lies au syndrome x
PCT/NO1999/000135 WO1999058121A1 (fr) 1998-05-08 1999-04-23 Nouveaux analogues d'acides gras destines au traitement de l'obesite, de l'hypertension et de la steatose hepatique
NO20005461A NO20005461L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever

Publications (2)

Publication Number Publication Date
NO20005461D0 NO20005461D0 (no) 2000-10-30
NO20005461L true NO20005461L (no) 2001-01-08

Family

ID=19907879

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20005461A NO20005461L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever
NO20005462A NO333143B1 (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av diabetes
NO20005463A NO20005463L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20005462A NO333143B1 (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av diabetes
NO20005463A NO20005463L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose

Country Status (17)

Country Link
US (4) US6441036B1 (fr)
EP (5) EP1075258B1 (fr)
JP (3) JP5057003B2 (fr)
KR (3) KR100701503B1 (fr)
CN (3) CN1245157C (fr)
AT (5) ATE336239T1 (fr)
AU (4) AU7240398A (fr)
BR (2) BR9910297A (fr)
CA (3) CA2331408C (fr)
DE (5) DE69932864D1 (fr)
DK (3) DK1075259T3 (fr)
ES (3) ES2207253T3 (fr)
NO (3) NO20005461L (fr)
NZ (3) NZ508047A (fr)
PT (2) PT1075258E (fr)
RU (3) RU2221558C2 (fr)
WO (4) WO1999058120A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275140A2 (fr) 2004-07-19 2011-01-19 Thia Medica AS Composition comprenant de l'huile de plantes ou de poisson et des components contenants des acides gras non-oxidables
WO2014140934A2 (fr) 2013-03-11 2014-09-18 Life Science Nutrition As Lipides naturels contenant des acides gras non oxydables

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058120A1 (fr) * 1998-05-08 1999-11-18 Rolf Berge Utilisation d'analogues d'acides gras non beta-oxydables pour traiter les etats lies au syndrome x
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
CA2704975A1 (fr) * 1999-10-13 2001-05-31 Marco A. Chacon Intervention therapeutique visant a reproduire l'effet d'une restriction calorique
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
ATE495740T1 (de) * 2002-05-28 2011-02-15 Ajinomoto Kk Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung
KR20050061400A (ko) 2002-06-20 2005-06-22 아이씨 벡 리미티드 황-함유 인지질 유도체
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
AU2003265886A1 (en) 2002-09-06 2004-03-29 Janssen Pharmaceutica N.V. (1H-Benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders
EP1558237A4 (fr) * 2002-09-27 2007-01-17 Martek Biosciences Corp Regulation glycemique amelioree dans le prediabete et/ou le diabete de type ii au moyen de l'acide docosahexaenoique
JP2006502213A (ja) * 2002-10-10 2006-01-19 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 脂肪族アルコール類の塩基性エステルおよび抗炎症薬または免疫調整薬としての使用
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
CA2515368A1 (fr) * 2003-02-13 2004-08-26 Luciano Rossetti Regulation de la prise alimentaire et de la production de glucose par modulation des niveaux d'acyl-coa gras de chaine longue dans l'hypothalamus
JP2006520335A (ja) * 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
CA2554735A1 (fr) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Molecules porteuses et therapeutiques
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
AU2005250603A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
RU2272628C1 (ru) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Способ быстрой оптимизации функций кровяных пластинок при метаболическом синдроме
RU2394598C2 (ru) * 2004-07-19 2010-07-20 Тиа Медика Ас Композиция, содержащая белковый материал и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
WO2006041922A2 (fr) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents, et procedes d'administration au systeme nerveux central
WO2006083439A2 (fr) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Procede permettant de diminuer l'homocysteine du serum
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
CN102050720B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
RU2441061C2 (ru) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
CA2666846C (fr) 2006-10-20 2018-04-10 Cpd, Llc Procede pour retablir l'effet de l'incretine
JP5552314B2 (ja) * 2006-11-01 2014-07-16 プロノヴァ バイオファーマ ノルゲ アーエス 新規脂質化合物
CN101535238A (zh) * 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
WO2008106091A1 (fr) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Utilisation de dérivés d'alcool à longue chaîne pour le traitement de l'alopécie aerata
WO2008106092A1 (fr) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Énantiomères d'ester octadéc-9-(z)énylique d'acide amino-phényl-acétique, leurs sels et leurs utilisations
EP2214481B1 (fr) 2007-10-15 2019-05-01 United Animal Health, Inc. Procédé permettant d'accroître la performance d'une progéniture
KR20100100818A (ko) * 2007-10-31 2010-09-15 프로노바 바이오파마 노르지 에이에스 새로운 ｄｈａ 유도체 및 약물로서 그들의 사용
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
ES2525340T3 (es) * 2008-04-29 2014-12-22 F. Hoffmann-La Roche Ag 4-butiratos de trimetilamonio como inhibidores de la CPT2
EP2147910A1 (fr) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Nouveaux composés lipidiques
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
CN102459142B (zh) 2009-05-08 2017-08-08 普罗诺瓦生物医药挪威公司 用于治疗与心血管、代谢和炎性疾病领域相关的疾病的多不饱和脂肪酸
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2012016048A1 (fr) 2010-07-28 2012-02-02 Life Technologies Corporation Composés antiviraux contenant un azide
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
EA028535B1 (ru) 2010-11-05 2017-11-30 Пронова Биофарма Норге Ас Способы лечения с применением липидных соединений
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
AU2014222389B2 (en) 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA3052449C (fr) 2013-03-11 2021-10-19 Jan Remmereit Compositions de lipides comportant un acide 5,11,14-eicosatrienoique et acides linoleiques conjugues
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
CN107405343A (zh) 2014-11-07 2017-11-28 明尼苏达大学董事会 可用于治疗疾病的盐和组合物
WO2016173923A1 (fr) 2015-04-28 2016-11-03 Pronova Biopharma Norge As Utilisation d'acides gras structurellement améliorés contenant du soufre pour prévenir et/ou traiter la stéatose hépatique non alcoolique
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
JP7312184B2 (ja) * 2017-10-23 2023-07-20 エピトラッカー インコーポレイテッド 脂肪酸アナログおよび代謝症候群に関連する症状の処置におけるそれらの使用
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
EP3796976A4 (fr) 2018-05-23 2022-03-30 Epitracker, Inc. Compositions et méthodes pour le diagnostic et le traitement d'affections liées à la longévité et à la qualité du vieillissement
EP3908374A4 (fr) 2019-01-09 2022-12-28 Epitracker, Inc. Compositions et méthodes pour le diagnostic et le traitement de maladies neurodégénératives
JP7404382B2 (ja) * 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
US12370166B2 (en) 2021-11-03 2025-07-29 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
KR20250043868A (ko) 2023-09-22 2025-03-31 건국대학교 산학협력단 옥시리핀을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
EP0833624B1 (fr) * 1995-06-07 2007-11-07 Poniard Pharmaceuticals, Inc. Prevention et traitement de pathologies cardio-vasculaires au moyen d'analogues de tamoxifene
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DK0843972T3 (da) * 1996-11-20 2002-12-02 Nutricia Nv Næringsmiddelsammensætning, der indeholder fedtstoffer til behandling af stofskiftesygdomme
WO1999058120A1 (fr) * 1998-05-08 1999-11-18 Rolf Berge Utilisation d'analogues d'acides gras non beta-oxydables pour traiter les etats lies au syndrome x

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275140A2 (fr) 2004-07-19 2011-01-19 Thia Medica AS Composition comprenant de l'huile de plantes ou de poisson et des components contenants des acides gras non-oxidables
WO2014140934A2 (fr) 2013-03-11 2014-09-18 Life Science Nutrition As Lipides naturels contenant des acides gras non oxydables

Also Published As

Publication number Publication date
KR100701502B1 (ko) 2007-04-02
EP1075260B1 (fr) 2005-10-19
JP2002514596A (ja) 2002-05-21
EP1075260A2 (fr) 2001-02-14
NO20005462L (no) 2001-01-08
CN1245157C (zh) 2006-03-15
DK1075260T3 (da) 2006-02-06
WO1999058123A2 (fr) 1999-11-18
NO20005461D0 (no) 2000-10-30
KR100701503B1 (ko) 2007-04-02
CN1300211A (zh) 2001-06-20
JP5057003B2 (ja) 2012-10-24
ES2207253T3 (es) 2004-05-16
AU4936699A (en) 1999-11-29
ATE334666T1 (de) 2006-08-15
AU4936799A (en) 1999-11-29
US6417232B1 (en) 2002-07-09
US6441036B1 (en) 2002-08-27
EP1075259A1 (fr) 2001-02-14
DK1075259T3 (da) 2003-11-03
EP1075259B1 (fr) 2003-07-23
EP1075258A1 (fr) 2001-02-14
JP4465672B2 (ja) 2010-05-19
HK1034911A1 (en) 2001-11-09
CN1300212A (zh) 2001-06-20
ATE336239T1 (de) 2006-09-15
US7026356B2 (en) 2006-04-11
CN1244323C (zh) 2006-03-08
CA2331393A1 (fr) 1999-11-18
DE69932645D1 (de) 2006-09-14
CN1302204A (zh) 2001-07-04
AU762790B2 (en) 2003-07-03
ES2251218T3 (es) 2006-04-16
EP1284139A1 (fr) 2003-02-19
RU2221558C2 (ru) 2004-01-20
JP2002514594A (ja) 2002-05-21
HK1034912A1 (en) 2001-11-09
CA2331393C (fr) 2009-08-11
AU762792B2 (en) 2003-07-03
RU2223095C2 (ru) 2004-02-10
NZ508045A (en) 2003-08-29
CA2331408A1 (fr) 1999-11-18
AU7240398A (en) 1999-11-29
HK1034909A1 (en) 2001-11-09
BR9910297A (pt) 2002-01-02
WO1999058123A3 (fr) 2000-03-09
DK1075258T3 (da) 2003-12-01
NO20005463L (no) 2001-01-08
CA2331395A1 (fr) 1999-11-18
KR100822077B1 (ko) 2008-04-14
DE69909775D1 (de) 2003-08-28
EP1075258B1 (fr) 2003-08-20
NO333143B1 (no) 2013-03-18
NZ508046A (en) 2003-08-29
ES2204142T3 (es) 2004-04-16
CA2331408C (fr) 2008-10-21
US6365628B1 (en) 2002-04-02
AU5451799A (en) 1999-11-29
NO20005463D0 (no) 2000-10-30
DE69909775T2 (de) 2004-06-03
NZ508047A (en) 2003-05-30
PT1075258E (pt) 2004-01-30
DE69910559D1 (de) 2003-09-25
JP2002514595A (ja) 2002-05-21
DE69927805D1 (de) 2006-03-02
CA2331395C (fr) 2008-10-14
PT1075259E (pt) 2003-12-31
DE69927805T2 (de) 2006-07-06
KR20010043314A (ko) 2001-05-25
DE69910559T2 (de) 2004-06-17
WO1999058120A1 (fr) 1999-11-18
BR9910296A (pt) 2002-01-15
EP1285652B1 (fr) 2006-08-16
EP1284139B1 (fr) 2006-08-02
ATE245416T1 (de) 2003-08-15
KR20010043315A (ko) 2001-05-25
RU2219920C2 (ru) 2003-12-27
CN1223343C (zh) 2005-10-19
KR20010043316A (ko) 2001-05-25
ATE247464T1 (de) 2003-09-15
NO20005462D0 (no) 2000-10-30
AU761355B2 (en) 2003-06-05
US20020198259A1 (en) 2002-12-26
WO1999058122A1 (fr) 1999-11-18
ATE306916T1 (de) 2005-11-15
DE69932864D1 (de) 2006-09-28
WO1999058121A1 (fr) 1999-11-18
EP1285652A1 (fr) 2003-02-26

Similar Documents

Publication Publication Date Title
NO20005461L (no) Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
CA2288445A1 (fr) Derives de l'acide pyrrolid-2-one-5-hydroxamique
BG103485A (en) Ketobanzamides as calpain inhibitors
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
ATE354622T1 (de) Flüssigkristallines medium
DK1144365T3 (da) Inhibitorer af alfa4beta1-medieret celleadhæsion
ATE224385T1 (de) Kristallmodifikation der liponsäure
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
BR0212899A (pt) Compostos orgânicos
DK1204659T3 (da) Serotonerge benzofuraner
ATE158301T1 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
MY122924A (en) Methods and compositions for inhibiting polymerization of vinyl monomers.
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
YU31502A (sh) Kristali kao inhibitori natrijum-vodonik izmenjivača tip1
GB0224306D0 (en) Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
ATE364594T1 (de) (4-acylaminopiperidin-1-yl)acetamide als neurokininantagonisten
YU70799A (sh) Derivati tiazofurina
ATE252565T1 (de) N,n'-disubstituierte n-(2-hydroxyalkyl)- harnstoffe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application